|
| Tuesday, 7 September 2010, 15:15 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Sept 7, 2010 - (ACN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.
Bendamustine is the subject of a license agreement concluded between the two companies in May 2009, in which SymBio granted Eisai the exclusive rights to develop and market the agent in Singapore and South Korea. A regulatory application seeking approval of bendamustine was submitted to the Singapore health authorities (Health Sciences Authority: HSA) by SymBio on December 24, 2008 and was approved on January 20, 2010. The product will be marketed by Eisai (Singapore) Pte. Ltd.
Approximately 300 people in Singapore are newly diagnosed with non-Hodgkin's lymphoma each year. It is well-known that many low-grade non-Hodgkin's lymphoma patients are prone to repeated relapse after responding to initial treatment, making further treatment difficult despite extended overall survival.
Bendamustine has been used for many years in Germany as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphatic leukemia. It is also available in the United States, where it was approved by the U.S. Food and Drug Administration in March 2008 for the treatment for chronic lymphatic leukemia and in October the same year for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma. In Japan, SymBio submitted a Marketing Authorization Application to the Japanese Ministry of Health, Labour and Welfare seeking approval of bendamustine for the treatment of recurrent or refractory low-grade non-Hodgkin's' lymphoma and mantle cell lymphoma. On August 30, 2010, the Pharmaceutical Affairs Committee of the Ministry's Pharmaceutical Affairs and Food Sanitation Council recommended bendamustine for final approval. If approved, Eisai will market the drug exclusively in Japan.
By launching bendamustine in Singapore, SymBio and Eisai seek to provide a new treatment option for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia, thereby making further contributions to improving the quality of life of patients living with these diseases.
About Bendamustine Hydrochloride
SymBio Pharmaceuticals Limited acquired the exclusive rights to develop and market bendamustine hydrochloride in Japan, China, South Korea, Taiwan and Singapore from Astellas Deutschland GmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH). Bendamustine was originally synthesized by German (formerly 'East German') pharmaceutical company Jenapharm and is currently marketed in Germany under the brand name of Ribomustin(R) as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. In the United States, the product has been approved by the U.S. Food and Drug Administration and is currently prescribed under the brand name Treanda(R) for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida, who previously served as corporate vice president of Amgen Ltd. and president of Amgen Japan. The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address the unmet medical needs of patients in Japan and the Asia Pacific region by cultivating a mutually beneficial or symbiotic relationship among key players in the healthcare industry (i.e. physicians, scientists, investors, government, and patients). For more information about SymBio Pharmaceuticals Limited, please visit www.symbiosis.co.jp/en/index.html.
Contact:
Tomoyuki Watanabe, Director,
Finance & Accounting
SymBio Pharmaceuticals Limited
Tel +81-3-5472-1125
Public Relations
Eisai Co., Ltd.
Tel +81-3-3817-5120
Topic: New market for product
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Nov 20, 2024 10:51 HKT/SGT |
|
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan |
| Nov 20, 2024 09:24 HKT/SGT |
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Nov 15, 2024 16:33 HKT/SGT |
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Nov 15, 2024 13:31 HKT/SGT |
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Nov 5, 2024 10:35 HKT/SGT |
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| Nov 1, 2024 12:56 HKT/SGT |
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Oct 31, 2024 12:56 HKT/SGT |
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Oct 31, 2024 10:33 HKT/SGT |
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Oct 17, 2024 19:01 HKT/SGT |
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Oct 17, 2024 14:59 HKT/SGT |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia |
| More news >> |
 |
|
|
|
